In an open letter published on Friday, Unity’s president and general manager Marc Whitten apologized for the controversial changes announced on September 12 and announced that it was walking back some ...
UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results